Anticancer Fund Research Grant RFA – Secondary Analysis of Trial Data

Funding for projects focusing on secondary analysis of data from cancer clinical trials to address research questions beyond the original study objectives.

The Anticancer Fund is requesting proposals for projects involving secondary data analysis of data from clinical cancer trials to address new research questions that are beyond the original study objectives.

Proposals should focus on research questions aligned with the Anticancer Fund’s overall mission: to innovate with existing therapeutic tools to improve survival outcomes.

Projects may address a broad range of cancer types, patient demographics, or interventions and should aim to optimise treatment regimens, identify benefiting patient subgroups, or address other treatment gaps. Project outcomes should ultimately inform a more personalised therapeutic decision-making in well-defined patient populations. Proposals should outline a clear plan for utilising clinical trial data to address the research question with a focus on changing clinical practice or generating the evidence necessary to justify a future prospective clinical trial.

Projects eligible for support could include, for example:

• Evaluation of treatment efficacy in well-defined sub-groups.
• Analysis of a pre-therapeutic (therefore predictive) & routinely available (bio-)marker to inform a therapeutic benefit.
• Evaluating whether variations of dose/schedule/combination/concomitant medications provide a survival benefit.
• Investigating the effect of a given intervention on a long-term important outcome that was initially not planned to be measured/collected.